S2WA34 Stock Overview
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Shockwave Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$93.65 |
| 52 Week High | US$96.20 |
| 52 Week Low | US$46.75 |
| Beta | 0.88 |
| 1 Month Change | 22.71% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 120.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| S2WA34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -0.9% | 0.5% | 0.4% |
| 1Y | n/a | -1.7% | 14.6% |
Return vs Industry: Insufficient data to determine how S2WA34 performed against the BR Medical Equipment industry.
Return vs Market: Insufficient data to determine how S2WA34 performed against the BR Market.
Price Volatility
| S2WA34 volatility | |
|---|---|
| S2WA34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: S2WA34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine S2WA34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,468 | Doug Godshall | shockwavemedical.com |
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina.
Shockwave Medical, Inc. Fundamentals Summary
| S2WA34 fundamental statistics | |
|---|---|
| Market cap | R$63.29b |
| Earnings (TTM) | R$753.05m |
| Revenue (TTM) | R$3.73b |
84.0x
P/E Ratio17.0x
P/S RatioIs S2WA34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S2WA34 income statement (TTM) | |
|---|---|
| Revenue | US$730.23m |
| Cost of Revenue | US$95.39m |
| Gross Profit | US$634.84m |
| Other Expenses | US$487.56m |
| Earnings | US$147.28m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | 3.93 |
| Gross Margin | 86.94% |
| Net Profit Margin | 20.17% |
| Debt/Equity Ratio | 109.4% |
How did S2WA34 perform over the long term?
See historical performance and comparison